Jennifer A. Korchak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer A. Korchak has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Gloria M. Sheynkman
Department of Molecular Physiology and Biological Physics, University of Virginia , Charlottesville, VA 22903
3 shared publications Aidan Fenix
Department of Laboratory Medicine and Pathology
2 shared publicationsBen T. Jordan
Cancer Genomics Research Laboratory
2 shared publicationsEmily F. Watts
Department of Molecular Physiology and Biological Physics
2 shared publications- Mathias Wilhelm
Computational Mass Spectrometry, School of Life Sciences, Technical University of Munich, Freising, Germany
2 shared publications Saikat Bandyopadhyay
Department of Molecular Physiology and Biological Physics
2 shared publications
Latest Publications
- Open Access
Extracellular Vesicles Derived from VEGF mRNA-Engineered Mesenchymal Stem Cells Promote Endothelial Cell Survival
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) exhibit great therapeutic potential in ischemia-associated conditions and diseases such as myocardial infarction, ischemic stroke, and wound healing. Enhancing the therapeutic efficacy of MSC-EVs could advance their clinical application. Diverse cargos (proteins, mRNA, microRNA, etc.) in MSC-EVs contribute to the therapeutic effects in various diseases. Vascular endothelial growth factor (VEGF) is one of the primary driving molecules in promoting angiogenesis and protecting endothelial cells lining blood vessels from apoptosis. In this study, we explored the feasibility of engineering parent MSCs with VEGF mRNA to potentiate therapeutic effects of their derived EVs. We first detected elevated levels of VEGF mRNA and protein in transfected MSCs and demonstrated the bioactivity of secreted VEGF by an angiogenesis assay. Furthermore, EVs derived from VEGF mRNA-engineered MSCs (VEGF-MSC-EVs) contained high levels of VEGF mRNA and protein and showed superior ability to protect human umbilical vein endothelial cells (HUVECs) from apoptosis compared to EVs derived from control MSCs (control MSC-EVs). To our knowledge, this is the first report demonstrating that VEGF-MSC-EVs boost therapeutic efficacy by promoting endothelial cell survival. Our findings offer a novel approach for cell-free therapy in ischemia-associated conditions and diseases.
Open AccessExtracellular Vesicles Derived from VEGF mRNA-Engineered Mesenchymal Stem Cells Promote Endothelial Cell Survival
Extracellular vesicles derived from mesenchymal stem cells (MSC-EVs) exhibit great therapeutic potential in ischemia-associated conditions and diseases such as myocardial infarction, ischemic stroke, and wound healing. Enhancing the therapeutic efficacy of MSC-EVs could advance their clinical application. Diverse cargos (proteins, mRNA, microRNA, etc.) in MSC-EVs contribute to the therapeutic effects in various diseases. Vascular endothelial growth factor (VEGF) is one of the primary driving molecules in promoting angiogenesis and protecting endothelial cells lining blood vessels from apoptosis. In this study, we explored the feasibility of engineering parent MSCs with VEGF mRNA to potentiate therapeutic effects of their derived EVs. We first detected elevated levels of VEGF mRNA and protein in transfected MSCs and demonstrated the bioactivity of secreted VEGF by an angiogenesis assay. Furthermore, EVs derived from VEGF mRNA-engineered MSCs (VEGF-MSC-EVs) contained high levels of VEGF mRNA and protein and showed superior ability to protect human umbilical vein endothelial cells (HUVECs) from apoptosis compared to EVs derived from control MSCs (control MSC-EVs). To our knowledge, this is the first report demonstrating that VEGF-MSC-EVs boost therapeutic efficacy by promoting endothelial cell survival. Our findings offer a novel approach for cell-free therapy in ischemia-associated conditions and diseases.
- Top Cited Papers
- 5 January 2026
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 27 (4) , 271-291
Proteoform medicine: characterizing and targeting protein forms in human disease
Proteoforms are the diverse molecular protein species produced from a single gene through genetic variation, alternative splicing and post-translational modifications. They are the crucial link between genotype and phenotype. There are estimated to be more than one million distinct protein variants produced from ~20,000 protein-coding genes in a given cell, making these proteoforms a vast and largely uncharacterized dimension in biomedical research. This Review focuses on the role of proteoforms in human genetic diseases. We highlight cutting-edge technologies for the identification and characterization of proteoforms, including long-read transcriptomics and emerging methods for direct protein sequencing, and we present a network biology framework to explain how proteoforms can perturb the molecular interactions and cellular pathways underlying disease phenotypes. We believe that precision medicine will require precision proteomics. An increasing knowledge of proteoform biology from molecular, systems and clinical perspectives will guide future research, ultimately contributing to a more precise understanding of the molecular basis of disease and refined therapeutic interventions.
- 5 January 2026
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 27 (4) , 271-291
Top Cited PapersProteoform medicine: characterizing and targeting protein forms in human disease
Proteoforms are the diverse molecular protein species produced from a single gene through genetic variation, alternative splicing and post-translational modifications. They are the crucial link between genotype and phenotype. There are estimated to be more than one million distinct protein variants produced from ~20,000 protein-coding genes in a given cell, making these proteoforms a vast and largely uncharacterized dimension in biomedical research. This Review focuses on the role of proteoforms in human genetic diseases. We highlight cutting-edge technologies for the identification and characterization of proteoforms, including long-read transcriptomics and emerging methods for direct protein sequencing, and we present a network biology framework to explain how proteoforms can perturb the molecular interactions and cellular pathways underlying disease phenotypes. We believe that precision medicine will require precision proteomics. An increasing knowledge of proteoform biology from molecular, systems and clinical perspectives will guide future research, ultimately contributing to a more precise understanding of the molecular basis of disease and refined therapeutic interventions.
- Open Access
- 16 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 35 (11) , 2614-2630
IS-PRM-Based Peptide Targeting Informed by Long-Read Sequencing for Alternative Proteome Detection
Alternative splicing is a major contributor of transcriptomic complexity, but the extent to which transcript isoforms are translated into stable, functional protein isoforms is unclear. Furthermore, detection of relatively scarce isoform-specific peptides is challenging, with many protein isoforms remaining uncharted due to technical limitations. Recently, a family of advanced targeted MS strategies, termed internal standard parallel reaction monitoring (IS-PRM), have demonstrated multiplexed, sensitive detection of predefined peptides of interest. Such approaches have not yet been used to confirm existence of novel peptides. Here, we present a targeted proteogenomic approach that leverages sample-matched long-read RNA sequencing (lrRNA-seq) data to predict potential protein isoforms with prior transcript evidence. Predicted tryptic isoform-specific peptides, which are specific to individual gene product isoforms, serve as "triggers" and "targets" in the IS-PRM method, Tomahto. Using the model human stem cell line WTC11, LR RNaseq data were generated and used to inform the generation of synthetic standards for 192 isoform-specific peptides (114 isoforms from 55 genes). These synthetic "trigger" peptides were labeled with super heavy tandem mass tags (TMT) and spiked into TMT-labeled WTC11 tryptic digest, predicted to contain corresponding endogenous "target" peptides. Compared to DDA mode, Tomahto increased detectability of isoforms by 3.6-fold, resulting in the identification of five previously unannotated isoforms. Our method detected protein isoform expression for 43 out of 55 genes corresponding to 54 resolved isoforms. This lrRNA-seq-informed Tomahto targeted approach is a new modality for generating protein-level evidence of alternative isoforms─a critical first step in designing functional studies and eventually clinical assays.
- 16 July 2024
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 35 (11) , 2614-2630
Open AccessIS-PRM-Based Peptide Targeting Informed by Long-Read Sequencing for Alternative Proteome Detection
Alternative splicing is a major contributor of transcriptomic complexity, but the extent to which transcript isoforms are translated into stable, functional protein isoforms is unclear. Furthermore, detection of relatively scarce isoform-specific peptides is challenging, with many protein isoforms remaining uncharted due to technical limitations. Recently, a family of advanced targeted MS strategies, termed internal standard parallel reaction monitoring (IS-PRM), have demonstrated multiplexed, sensitive detection of predefined peptides of interest. Such approaches have not yet been used to confirm existence of novel peptides. Here, we present a targeted proteogenomic approach that leverages sample-matched long-read RNA sequencing (lrRNA-seq) data to predict potential protein isoforms with prior transcript evidence. Predicted tryptic isoform-specific peptides, which are specific to individual gene product isoforms, serve as "triggers" and "targets" in the IS-PRM method, Tomahto. Using the model human stem cell line WTC11, LR RNaseq data were generated and used to inform the generation of synthetic standards for 192 isoform-specific peptides (114 isoforms from 55 genes). These synthetic "trigger" peptides were labeled with super heavy tandem mass tags (TMT) and spiked into TMT-labeled WTC11 tryptic digest, predicted to contain corresponding endogenous "target" peptides. Compared to DDA mode, Tomahto increased detectability of isoforms by 3.6-fold, resulting in the identification of five previously unannotated isoforms. Our method detected protein isoform expression for 43 out of 55 genes corresponding to 54 resolved isoforms. This lrRNA-seq-informed Tomahto targeted approach is a new modality for generating protein-level evidence of alternative isoforms─a critical first step in designing functional studies and eventually clinical assays.
- Open Access
IS-PRM-based peptide targeting informed by long-read sequencing for alternative proteome detection
Alternative splicing is a major contributor of transcriptomic complexity, but the extent to which transcript isoforms are translated into stable, functional protein isoforms is unclear. Furthermore, detection of relatively scarce isoform-specific peptides is challenging, with many protein isoforms remaining uncharted due to technical limitations. Recently, a family of advanced targeted MS strategies, termed internal standard parallel reaction monitoring (IS-PRM), have demonstrated multiplexed, sensitive detection of pre-defined peptides of interest. Such approaches have not yet been used to confirm existence of novel peptides. Here, we present a targeted proteogenomic approach that leverages sample-matched long-read RNA sequencing (LR RNAseq) data to predict potential protein isoforms with prior transcript evidence. Predicted tryptic isoform-specific peptides, which are specific to individual gene product isoforms, serve as “triggers” and “targets” in the IS-PRM method, Tomahto. Using the model human stem cell line WTC11, LR RNAseq data were generated and used to inform the generation of synthetic standards for 192 isoform-specific peptides (114 isoforms from 55 genes). These synthetic “trigger” peptides were labeled with super heavy tandem mass tags (TMT) and spiked into TMT-labeled WTC11 tryptic digest, predicted to contain corresponding endogenous “target” peptides. Compared to DDA mode, Tomahto increased detectability of isoforms by 3.6-fold, resulting in the identification of five previously unannotated isoforms. Our method detected protein isoform expression for 43 out of 55 genes corresponding to 54 resolved isoforms. This LR RNA seq-informed Tomahto targeted approach, called LRP-IS-PRM, is a new modality for generating protein-level evidence of alternative isoforms – a critical first step in designing functional studies and eventually clinical assays.
Open AccessIS-PRM-based peptide targeting informed by long-read sequencing for alternative proteome detection
Alternative splicing is a major contributor of transcriptomic complexity, but the extent to which transcript isoforms are translated into stable, functional protein isoforms is unclear. Furthermore, detection of relatively scarce isoform-specific peptides is challenging, with many protein isoforms remaining uncharted due to technical limitations. Recently, a family of advanced targeted MS strategies, termed internal standard parallel reaction monitoring (IS-PRM), have demonstrated multiplexed, sensitive detection of pre-defined peptides of interest. Such approaches have not yet been used to confirm existence of novel peptides. Here, we present a targeted proteogenomic approach that leverages sample-matched long-read RNA sequencing (LR RNAseq) data to predict potential protein isoforms with prior transcript evidence. Predicted tryptic isoform-specific peptides, which are specific to individual gene product isoforms, serve as “triggers” and “targets” in the IS-PRM method, Tomahto. Using the model human stem cell line WTC11, LR RNAseq data were generated and used to inform the generation of synthetic standards for 192 isoform-specific peptides (114 isoforms from 55 genes). These synthetic “trigger” peptides were labeled with super heavy tandem mass tags (TMT) and spiked into TMT-labeled WTC11 tryptic digest, predicted to contain corresponding endogenous “target” peptides. Compared to DDA mode, Tomahto increased detectability of isoforms by 3.6-fold, resulting in the identification of five previously unannotated isoforms. Our method detected protein isoform expression for 43 out of 55 genes corresponding to 54 resolved isoforms. This LR RNA seq-informed Tomahto targeted approach, called LRP-IS-PRM, is a new modality for generating protein-level evidence of alternative isoforms – a critical first step in designing functional studies and eventually clinical assays.
- 3 November 2022
- Published by Wiley in Transfusion
- Vol. 63 (2) , 279-287
How do we assess batch‐to‐batch consistency between extracellular vesicle products?
Background: Extracellular vesicles (EVs) have gained interest in the field of regenerative and transfusion medicine. Specifically, current Good Manufacturing Practice (cGMP)‐grade EVs produced by mesenchymal stromal cells (MSCs) are an intriguing option for cell‐free therapeutics. With the development of cGMP‐grade EV products, a simple and reliable method for batch‐to‐batch consistency is needed.Study Design and Methods: The objective of this study was to validate a method to semiquantitatively assess the batch‐to‐batch consistency of isolated EVs. A multiplex bead‐based flow cytometric assay containing 37 surface markers and 2 assay control antibody‐coated capture beads was validated. Detection limits (n = 10 buffer samples), repeatability (n = 9 EV samples), and intra‐observer reproducibility over 2 days (n = 10 EV batches) were assessed. A Spearman correlation matrix was used to evaluate the batch‐to‐batch consistency of independently isolated EV products (n = 37 surface markers). Batches with a Spearman correlation coefficient ≥0.9 and p < 0.05 were considered statistically indistinguishable from previous batches.Results: This assay demonstrated robust repeatability as well as intra‐ and inter‐assay reproducibility. In‐house batches of EVs were significantly correlated (r ≥ 0.90; p ≤ 1×10−14). Compared with buffer, EV batches had correlation coefficients near zero (r ≤ −0.10; p ≥ 0.12). Commercially sourced EVs significantly correlated with in‐house EV batches, but fell below the 90% correlation cutoff (r ≤ 0.71; p ≤ 0.0004).Discussion: This time‐efficient and technically simple assay offers a robust method of quality control for assessing the batch‐to‐batch reproducibility of cGMP‐grade EV products.
- 3 November 2022
- Published by Wiley in Transfusion
- Vol. 63 (2) , 279-287
How do we assess batch‐to‐batch consistency between extracellular vesicle products?
Background: Extracellular vesicles (EVs) have gained interest in the field of regenerative and transfusion medicine. Specifically, current Good Manufacturing Practice (cGMP)‐grade EVs produced by mesenchymal stromal cells (MSCs) are an intriguing option for cell‐free therapeutics. With the development of cGMP‐grade EV products, a simple and reliable method for batch‐to‐batch consistency is needed.Study Design and Methods: The objective of this study was to validate a method to semiquantitatively assess the batch‐to‐batch consistency of isolated EVs. A multiplex bead‐based flow cytometric assay containing 37 surface markers and 2 assay control antibody‐coated capture beads was validated. Detection limits (n = 10 buffer samples), repeatability (n = 9 EV samples), and intra‐observer reproducibility over 2 days (n = 10 EV batches) were assessed. A Spearman correlation matrix was used to evaluate the batch‐to‐batch consistency of independently isolated EV products (n = 37 surface markers). Batches with a Spearman correlation coefficient ≥0.9 and p < 0.05 were considered statistically indistinguishable from previous batches.Results: This assay demonstrated robust repeatability as well as intra‐ and inter‐assay reproducibility. In‐house batches of EVs were significantly correlated (r ≥ 0.90; p ≤ 1×10−14). Compared with buffer, EV batches had correlation coefficients near zero (r ≤ −0.10; p ≥ 0.12). Commercially sourced EVs significantly correlated with in‐house EV batches, but fell below the 90% correlation cutoff (r ≤ 0.71; p ≤ 0.0004).Discussion: This time‐efficient and technically simple assay offers a robust method of quality control for assessing the batch‐to‐batch reproducibility of cGMP‐grade EV products.